End-of-day quote
Korea S.E.
18:00:00 2024-05-09 EDT
|
5-day change
|
1st Jan Change
|
21,400
KRW
|
+0.23%
|
|
-3.60%
|
-22.18%
|
Fiscal Period: December |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Capitalization
1 |
725,681
|
761,628
|
703,085
|
652,094
|
1,347,135
|
1,351,191
|
Enterprise Value (EV)
1 |
568,991
|
594,231
|
575,452
|
515,826
|
1,206,656
|
1,218,468
|
P/E ratio
|
44
x
|
27.2
x
|
22.5
x
|
25.8
x
|
98.7
x
|
33.8
x
|
Yield
|
1.69%
|
3.66%
|
2.79%
|
3.46%
|
1.97%
|
-
|
Capitalization / Revenue
|
14.2
x
|
11.8
x
|
11.7
x
|
11
x
|
19.5
x
|
17.1
x
|
EV / Revenue
|
11.1
x
|
9.18
x
|
9.54
x
|
8.73
x
|
17.5
x
|
15.4
x
|
EV / EBITDA
|
26.2
x
|
15.9
x
|
16.9
x
|
17.1
x
|
32.6
x
|
26.9
x
|
EV / FCF
|
43.4
x
|
10
x
|
-81.4
x
|
26.5
x
|
72.4
x
|
200
x
|
FCF Yield
|
2.31%
|
9.96%
|
-1.23%
|
3.77%
|
1.38%
|
0.5%
|
Price to Book
|
3.52
x
|
3.51
x
|
3.43
x
|
3.11
x
|
6.24
x
|
5.94
x
|
Nbr of stocks (in thousands)
|
51,176
|
49,780
|
49,030
|
49,030
|
49,130
|
49,134
|
Reference price
2 |
14,180
|
15,300
|
14,340
|
13,300
|
27,420
|
27,500
|
Announcement Date
|
19-03-18
|
20-04-06
|
21-03-19
|
22-03-18
|
23-03-14
|
24-03-11
|
Fiscal Period: December |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Net sales
1 |
51,211
|
64,699
|
60,295
|
59,088
|
69,098
|
79,210
|
EBITDA
1 |
21,703
|
37,445
|
34,062
|
30,145
|
37,053
|
45,342
|
EBIT
1 |
19,744
|
35,375
|
31,978
|
28,109
|
33,603
|
40,360
|
Operating Margin
|
38.55%
|
54.68%
|
53.04%
|
47.57%
|
48.63%
|
50.95%
|
Earnings before Tax (EBT)
1 |
22,486
|
38,921
|
36,084
|
33,581
|
34,457
|
49,572
|
Net income
1 |
16,491
|
28,070
|
31,478
|
25,318
|
27,267
|
39,930
|
Net margin
|
32.2%
|
43.39%
|
52.21%
|
42.85%
|
39.46%
|
50.41%
|
EPS
2 |
322.5
|
562.7
|
638.6
|
516.4
|
277.8
|
813.0
|
Free Cash Flow
1 |
13,123
|
59,179
|
-7,069
|
19,460
|
16,675
|
6,080
|
FCF margin
|
25.63%
|
91.47%
|
-11.72%
|
32.93%
|
24.13%
|
7.68%
|
FCF Conversion (EBITDA)
|
60.47%
|
158.04%
|
-
|
64.56%
|
45%
|
13.41%
|
FCF Conversion (Net income)
|
79.58%
|
210.83%
|
-
|
76.86%
|
61.16%
|
15.23%
|
Dividend per Share
2 |
240.0
|
560.0
|
400.0
|
460.0
|
540.0
|
-
|
Announcement Date
|
19-03-18
|
20-04-06
|
21-03-19
|
22-03-18
|
23-03-14
|
24-03-11
|
Fiscal Period: December |
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
---|
Net sales
1 |
24.67
|
18.38
|
18.72
|
17.44
|
EBITDA
|
-
|
-
|
-
|
-
|
EBIT
1 |
12.52
|
7.636
|
9.875
|
10.34
|
Operating Margin
|
50.77%
|
41.54%
|
52.76%
|
59.3%
|
Earnings before Tax (EBT)
|
-
|
-
|
-
|
-
|
Net income
1 |
-
|
7.439
|
9.8
|
8.544
|
Net margin
|
-
|
40.47%
|
52.36%
|
48.99%
|
EPS
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
Announcement Date
|
23-05-04
|
23-08-09
|
23-11-10
|
24-02-05
|
Fiscal Period: December |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Net Debt
1 |
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
1 |
156,690
|
167,398
|
127,633
|
136,268
|
140,479
|
132,724
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
13,123
|
59,179
|
-7,069
|
19,460
|
16,675
|
6,080
|
ROE (net income / shareholders' equity)
|
7.83%
|
13.3%
|
14.9%
|
12.1%
|
12.8%
|
18%
|
ROA (Net income/ Total Assets)
|
5.6%
|
9.81%
|
8.91%
|
7.93%
|
9.11%
|
10.5%
|
Assets
1 |
294,510
|
286,155
|
353,123
|
319,449
|
299,157
|
380,974
|
Book Value Per Share
2 |
4,032
|
4,359
|
4,184
|
4,277
|
4,396
|
4,626
|
Cash Flow per Share
2 |
344.0
|
436.0
|
326.0
|
454.0
|
105.0
|
642.0
|
Capex
1 |
2,276
|
6,159
|
21,080
|
3,888
|
1,544
|
8,155
|
Capex / Sales
|
4.44%
|
9.52%
|
34.96%
|
6.58%
|
2.24%
|
10.3%
|
Announcement Date
|
19-03-18
|
20-04-06
|
21-03-19
|
22-03-18
|
23-03-14
|
24-03-11
|
|
1st Jan change
|
Capi.
|
---|
| -22.18% | 768M | | +19.62% | 43.27B | | +24.52% | 22.92B | | +20.29% | 15.43B | | +7.48% | 12.95B | | +42.51% | 11.83B | | -8.84% | 6.91B | | -0.05% | 6.79B | | -8.87% | 5.73B | | +13.13% | 5.55B |
Generic Pharmaceuticals
|